To date, 20 percent of your genetic code is owned by someone else. About two-thirds of these patents belong to private companies, and one-third belong to universities. … Read More
Newegg scores new victory against "corporate troll" Alcatel-Lucent
For a few years now Newegg.com has made it policy never to settle with patent trolls. Following up from their victory over Soverain Software in January, who claimed to have invented the online shopping cart, now the retailer has scored another favorable verdict against French telecom equipment maker Alcatel-Lucent over… … Read More
Apple strips Swedish Whypod of its trademark
A Swedish company registered the product Whypod, evoking Apple’s fury over the product name being too similar to their iPod. The Swedish Patent and Registration Office found in favour of the American company. … Read More
WikiLeaks: Monsanto lobbied on taxpayers’ dime
Nonprofit consumer protection group Food & Water Watch published a report on Tuesday that demonstrates a partnership between the federal government and a number of controversial biotech companies that have slowly but surely pushed their GMO products on a number of new countries in recent years.At center stage in the report is Monsanto, the St. Louis, Missouri-based makers of genetically-modified crops and genetically-engineered seeds that has continuously generated criticism as of late over its practices both on the growing field and in a court of law. Monsanto is among the most valuable corporations in the US, yet has relentlessly sued small-time farmers across the world over alleged patent violations, often forcing independent agriculturists to go out of business. Legislation signed into law last month provided litigation immunity to GMO companies including Monsanto, and on Monday the Supreme Court sided with the corporation when ruling on a landmark patent infringement case.“The US Department of State is selling seeds instead of democracy,” Food & Water Watch Executive Director Wenonah Hauter told reporters. “This report provides a chilling snapshot of how a handful of giant biotechnology companies are unduly influencing US foreign policy and undermining our diplomatic efforts to promote security, international development and transparency worldwide. This report is a call to action for Americans because public policy should not be for sale to the highest bidder.”Food & Water Watch published their findings this week after combing through the roughly 260,000 State Department cables that the whistleblower website first began publishing in 2010, but notes that their statistics specifically come from memos not classified as “secret” or higher.For the most part, wrote the nonprofit, “The State Department strategy sought to foist pro-biotechpolicies on foreign governments” using a four-prong approach: promote biotech business interests; lobby foreign governments to weaken biotech rules; protect US biotech exports and press developing world to adopt biotech crops.As the cables are analyzed, though, the efforts the State Department undertook to advocate for Monsanto demonstrate a willingness to put a US-based company’s profits about the interests and health of those residing in foreign nations.In a cable sent from the Slovakian consulate in 2005, the State Department is told that the local post “will continue its efforts to dispel myths about GMOs and advocate on behalf of Monsanto.” In 2009, a cable out of Madrid, Spain announced that Monsanto had made “urgent requests” to fight off an anti-GMO opposition campaign that posed problems to the biotech industry. Other revelations show pro-GMO efforts waged by the US on behalf of the biotech industry in Hong Kong, the European Union, Egypt and elsewhere.“The State Department’s efforts impose the policy objectives of the largest biotech seed companies on often skeptical or resistant governments and public, and exemplifies thinly veiled corporate diplomacy,” alleged Food & Water Watch.When Food & Water Watch scoured those cables, they concluded that the State Department was conducting off-the-radar negotiations that didn’t seem to advance democracy or American ideals — instead, rather, it found evidence of lobbying used to advance the agenda of thriving US companies that have already purchased the approval of much of Washington.“It’s not surprising that Monsanto, DuPont, Syngenta, Bayer and Dow want to maintain and expand their control of the $15 billion global biotech seed market, but it’s appalling that the State Department is complicit in supporting their goals despite public and government opposition in several countries,” Ronnie Cummins, executive director of Organic Consumers Association, said in the press release accompanying the report. “American taxpayer’s money should not be spent advancing the goals of a few giant biotech companies.” Of the 926 State Department cables analyzed by Food & Water Watch, the group found Monsanto appeared in more than 6 percent of the memos, shining light on how a federal agency “worked especially hard to promote the interests” of an outside company.When reached for comment by Reuters, Monsanto spokesman Tom Helscher said, “We remain committed to sharing information so that individuals can better understand our business and our commitments to support farmers throughout the world as they work to meet the agriculture demands of our world’s growing population.” The State Department did not immediately respond to requests for comment.As RT reported previously, that so-called “Monsanto Protection Act” signed into law last month was co-authored by a senator that has received thousands of dollars in campaign contributions from the company — a revelation that didn’t surprise many given that another important figure in Washington, Justice Clarence Thomas, served as an attorney for the corporation before he was nominated to the high court only to eventually preside over a case involving his former employer. But according to Food & Water Watch, the relationship between Monsanto and the government extends beyond Congress and the Supreme Court. In a statement published on Tuesday to accompany their report, Food & Water Watch wrote that the cables detail “how the US State Department lobbies foreign governments to adopt pro-agricultural biotechnology policies and laws, operates a rigorous public relations campaign to improve the image of biotechnology and challenges commonsense biotechnology safeguards and rules — including opposing genetically engineered (GE) food labeling laws.”This week’s report comes just one day after Justice Thomas and the Supreme Court sided with Monsanto in reaching a decision in a landmark patent suit. In the case, the high court said that an Indiana farmer infringed on Monsanto’s patent rights by using specially-made seeds he obtained second-hand without signing a contract with the company. That ruling, however, came just days after the company was hit with comparably bad news: on Friday, the US Department of Agriculture ordered an extra round of tests for new GMO breeds being developed by Monsanto and Dow, putting on hold plans to release to the public laboratory-made crops that can withstand heavy dousing of dangerous pesticides. Both companies want to make available crops that are resistant to the chemicals 2,4-D and dicamba, a move that environmentalists fear will prompt farmers to use more of these toxins.”The danger that 2,4-D and dicamba pose is a real threat to crops…nearly every food crop,” Steve Smith, director of agriculture at Red Gold, told Reuters last year. … Read More
Jolie’s double mastectomy highlights Supreme Court ‘cancer gene’ patent battle
On Monday, Jolie told the world she had undergone the procedure after discovering she carries a gene called BRCA1, which drastically increases the risk of developing breast and ovarian cancer. Myriad Genetics, the Utah-based firm which owns both the patent to BRCA1 and a similar gene called BRCA2, saw its shares climb 4 percent on Tuesday following the starlet’s announcement, Yahoo!Finance reports. As the patent owner, Myriad has the exclusive right to test for those genes, keeping other biotech firms from developing their own diagnostic tools. Jolie, who underwent Myriad’s BRACAnalysis – which determines a woman’s risk of getting hereditary breast or ovarian cancer by looking for defects in the BRCA1 or BRCA2 genes –urged others to take the genetic tests as well. Her decision to not keep her story private was spurred by her desire to warn women “who do not know that they might be living under the shadow of cancer.” But with only one firm monopolizing research on the “faulty” genes, Jolie’s altruistic announcement pushed Myriad’s stock up to its highest level since mid-2009.Testing for the two genes costs roughly $3,340 dollars, though the molecular diagnostic company might soon see their profit base shrink amidst an ongoing Supreme Court case which could see such patents on nature nullified. In late November, the court decided to review whether companies can patent the process of taking the human gene out of the body for research, with arguments getting underway in April.The appeal to the Supreme Court was filed by the American Civil Liberties Union and the Public Patent Foundation on behalf of the Association for Molecular Pathology (AMP) and other professional organizations that represent more than 150,000 physicians and scientists.The coalition has banded together to fight against attempts to patent and financially exploit parts of the human body, which they argue are“products of nature.” The have further said the patents undermine the First Amendment by delimiting the free exchange of ideas related to the human body.“Gene patents prevent pathologists from reading their patients’ DNA sequences to assess their risks for disease, their prognoses, or their potential responsiveness to therapy,” the online health information site OncLive cites AMP president Iris Schrijver as saying last September.“The result of this lack of competition is increased test costs, decreased patient access, reduced innovation in the development of new test methods, and dramatically reduced knowledge dissemination.” The cancer groups initially won a court ruling in 2010, although an appeals court later found that genes could in fact be patented, as the very process of extracting genes differentiated them from the “natural” DNA in our bodies, the Wall Street Journal reported.In a scathing article published by Slate magazine on Sunday, world-renowned economist Joseph Stiglitz lambasted Myriad as “a true example of an American corporation for which profit trumps all other values, including the value of human life itself.”“It [Myriad] claims to own the rights to any test for the presence of the two critical genes associated with breast cancer, and it has ruthlessly enforced that right, though their test is inferior to one that Yale University was willing to provide at much lower cost. The consequences have been tragic: Thorough, affordable testing that identifies high-risk patients saves lives.” Myriad and other biotech firms argue that without the ability to have such patents – which they have now been obtaining for three decades – the lack of financial incentives would cause the industry to dry up.Currently, some 20 percent of the 4,000 genes found in the human body have been patented, including some linked to colon cancer and Alzheimer’s disease. Some patents are owned by research institutions which attempt to prevent their reduction to a strictly for profit tool.Myriad’s patents on BRCA1 and BRCA2 are set to expire in roughly two years. A ruling by the Supreme Court is expected later this year. … Read More
Monsanto taking over America’s agriculture: New victory in Supreme Court
http://www.youtube.com/v/r1W1diYklSU?version=3&f=videos&app=youtube_gdata Original article: Monsanto taking over America’s agriculture: New victory in Supreme Court
European Union backs Apple in Google-Motorola patent squabble
EU anti-trust officials said Monday that Google-owned Motorola was abusing its leading position in Germany’s mobile phones market by filing a patent injunction against Apple over certain core smartphone functions. A statement said that the European Union had reached a “preliminary…





